Exclusive Interview with Demetrix CEO Jeff Ubersax, PhD Biotechnology companies are hard at work finding ways to commercialize biosynthetic cannabinoids, and among those companies is Demetrix. CEO Jeff Ubersax...

This is a copy of the July 14th edition of our weekly Newsletter, which we have been publishing since October 2015. Friends, While the recent decline in the entire...

  Demetrix Secures $50 Million In Series A Funding To Provide Cannabinoids To Pharmaceutical, Supplement, And Consumer Product Companies Funding Round led by Tuatara Capital with Continued Participation by...